EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis

Katherine Longardner iD, Brenton A Wright, Aljoharah Alakkas, Hyeri You, Ronghui Xu, Lin Liu, Fatta B Nahab iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0278262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Katherine Longardner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America. Hauptthemen laut MEDLINE: Parkinson Disease, Psychotic Disorders, Antipsychotic Agents, Dementia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, ACADIA Pharmaceuticals, National Institutes of Health University of California San Diego Clinical and Translational Science Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown.

Aim

Expanding on prior work exploring mortality in treated PDP patients, we conducted a retrospective comparison to understand the links between treatment regimen, clinical characteristics, and negative outcomes.

Methods

Electronic medical record data extraction included clinically diagnosed PD patients between 4/29/16-4/29/19 and excluded patients with primary psychiatric diagnoses or atypical parkinsonism. Mortality and clinical characteristics during the study period were compared between untreated patients and those receiving pimavanserin, quetiapine, or both agents (combination). Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia.

Results

The pimavanserin group (n = 34) had lower mortality than the untreated group (n = 66) (odds ratio = 0.171, 95% confidence interval: 0.025–0.676, p = 0.026). The untreated group had similar mortality compared to the quetiapine (n = 147) and combination (n = 68) groups. All treated groups had a higher LEDD compared to the untreated group, but no other differences in demographics, hospitalizations, medical comorbidities, medications, or laboratory values were found between the untreated and treated groups.

Conclusions

PDP patients receiving pimavanserin had lower mortality than untreated patients. We found no other clear differences in clinical characteristics to explain the mortality risk. Prospective randomized trials are needed to definitively identify the optimal PDP treatment regimen and associated risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePsychotic DisordersAntipsychotic AgentsDementiaHumansAgedQuetiapine FumarateRetrospective StudiesProspective StudiesUreaLevodopaPiperidines

Substanzen

Quetiapine FumarateAntipsychotic AgentsUreaLevodopapimavanserinPiperidines

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
  • Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
  • Biostatistics Unit, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, United States of America.
  • Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, United States of America.

ORCID-Profile: Katherine Longardner, Fatta B Nahab

Förderung

  • NCATS NIH HHS
  • ACADIA Pharmaceuticals
  • National Institutes of Health University of California San Diego Clinical and Translational Science Award

Zitieren

APA

Longardner, K., Wright, B. A., Alakkas, A., You, H., Xu, R., Liu, L., & Nahab, F. B. (2023). Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0278262

Vancouver

Longardner K, Wright BA, Alakkas A, You H, Xu R, Liu L, et al. Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. PLOS ONE. 2023. doi:10.1371/journal.pone.0278262

BibTeX
@article{Longardner2023,
  author = {Longardner, Katherine and Wright, Brenton A and Alakkas, Aljoharah and You, Hyeri and Xu, Ronghui and Liu, Lin and Nahab, Fatta B},
  title = {Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0278262}
}
Kostenlos starten →